Articles tagged "Alloantibodies"

2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
J. Choi,¹ O. Aubert,² S. Louie,¹ N. Ammerman,¹ A. Vo,¹ A. Peng,¹ E. Huang,¹ R. Najjar,¹ D. Puliyanda,¹ S. Sethi,¹ M. Haas,¹ K. Lim,¹ A. Loupy,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Translational Center for Organ Transplantation, Paris, France.
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…
2018 American Transplant Congress
The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis
S. Wan,^1,2 T. Ying,^1,2 K. Wyburn,^1,2 D. Roberts,^3,4 M. Wyld,^1,2 S. Chadban.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia; ³Department of Renal Medicine, Canberra Hospital and Health Services, Canberra, Australia; ⁴Medical School, Australian National University, Canberra, Australia.
Introduction: Current treatment strategies for antibody-mediated rejection (AMR) in kidney transplantation are based on low quality data from a small number of controlled trials. Novel…
2018 American Transplant Congress
Complement Fixing Donor-Specific Antibodies Are Associated with Increased Risk of Chronic Lung Allograft Dysfunction after Lung Transplantation
C. Ensor,¹ C. Iasella,¹ M. Mangiola,¹ M. Marrari,¹ M. Morrell,¹ N. Shigemura,² J. DCunha,¹ J. McDyer,¹ A. Zeevi.¹
¹University of Pittsburgh, Pittsburgh, PA; ²Temple University, Philadelphia, PA.
Purpose: Survival among lung transplant recipients (LTRs) remains poor compared to other solid organs.The presence of donor-specific antibodies (DSA) directed against donor human leukocyte antigen…
2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
N. Bath, S. Parajuli, G. Leverson, M. Jorgenson, J. Fose, T. Ellis, D. Kaufman, A. Djamali, R. Redfield.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…
2018 American Transplant Congress
ABO-Incompatibility Lower Incidence of DSA-Induced Antibody-Mediated Rejection
D. Lee,¹ B. Kim,¹ J. KIm,¹ I. KIm,¹ M. Jeon.¹
¹Nephrology, Medicine, Maryknoll General Hospital, Busan, Republic of Korea; ²Laboratory Medicine, Maryknoll General Hospital, Busan, Republic of Korea; ³Surgery, Maryknoll General Hospital, Busan, Republic of Korea; ⁴Urology, Maryknoll General Hospital, Busan, Republic of Korea; ⁵Pathology, Maryknoll General Hospital, Busan, Republic of Korea.
Introduction:Donor-specific anti-HLA antibody (DSA) and Anti-ABO antibody are major barriers for successful kidney transplantation. Limited data are available about the existences of both DSA and…
2018 American Transplant Congress
Successful Desensitization with Carfilzomib-Based Regimen to Facilitate Lung Transplantation: Initial Experience
C. Ensor,¹ A. Zeevi,¹ M. Mangiola,¹ C. Iasella,¹ M. Marrari,¹ M. Morrell,¹ E. Lendermon,¹ S. Kilaru,¹ N. Shigemura,² J. DCunha,¹ J. McDyer.¹
¹University of Pittsburgh, Pittsburgh, PA; ²Temple University, Philadelphia, PA.
Purpose:We describe the successful desensitization of highly sensitized lung transplant candidates (LTCs) using plasma exchange (PLEX),intravenous immunoglobulin G(IVIg),and carfilzomib.Methods:5-patient case series of successful desensitization of…
2018 American Transplant Congress
The Impact of Donor Specific Alloantibodies on Long-Term Outcomes of Liver Re-Transplantation
Q. Xu,¹ A. Skaro,² V. McAlister.²
¹Department of Pathology and Lab Medicine, University of Western Ontario, London, ON, Canada; ²Department of Surgery, University of Western Ontario, London, ON, Canada.
Despite reports that associate donor specific antibody (DSA) with rejection after liver transplantation, grafts are still allocated according to blood group (ABO) but not human…
2018 American Transplant Congress
Mid-Term Outcome of Donor Specific Antibody Positive Deceased Donor Kidney Transplantation with Peri-Transplant Desensitization
K. Osickova,¹ P. Hruba,² J. Slatinska,¹ A. Slavcev,² J. Fronek,² E. Honsova,² O. Viklicky.¹
¹Dept. of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ²Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Donor specific HLA-antibodies (DSA) remain a large barrier to successful kidney transplantation and there is a limited knowledge about desensitization strategies in deceased donor programs.Anti…
2018 American Transplant Congress
Targeting Plasma Cells with Anti-CD38mAb (Daratumumab) and CXCR4 Antagonist (Plerixafor) for Desensitization
J. Kwun,¹ E. Brian,¹ M. Manook,¹ J. Park,¹ K. Freischlag,¹ J. Yoon,¹ J. Yi,¹ M. Stegall,² S. Knechtle.¹
¹Surgery, Duke University, Durham, NC; ²Surgery, Mayo Clinic, Rochester, MN.
[Introduction] Sensitized patients comprise a significant portion (30%) of candidates on the transplant waiting list. Unfortunately for sensitized patients, the presence of donor-specific antibodies (DSA)…
2018 American Transplant Congress
Kidney Allograft Vascular Disease Post-Transplant (KTX): Risk Factors and Implications
M. El Ters,¹ L. Cornell,² J. Grande,² F. Cosio.¹
¹Medicine, Mayo Clinic, Rochester, MN; ²Pathology, Mayo Clinic, Rochester, MN.
Background: Over time grafts develop arteriosclerosis (ART)and arteriolar hyalinosis (AH). Previous studies associated AH with calcineurin inhibitors (CNI), diabetes (DM), kidney age and hypertension. Other…